Acorda therapeutics implements corporate restructuring, provides q3 update

Acorda therapeutics implements corporate restructuring, provides third quarter 2019 update.acorda therapeutics inc - estimated 2020 operating expenses reduced by about $60 million compared to 2019 revised guidance.acorda therapeutics inc - total non-gaap operating expenses for full year 2020 expected to be $180 - $190 million.acorda therapeutics inc - inbrija and ampyra q3 2019 net sales of about $5 million and about $38 million, respectively.acorda therapeutics inc - estimates that it will incur about $8 million of pre-tax charges related to restructuring, through q1.acorda therapeutics inc - as part of this restructuring, acorda is reducing headcount by approximately 25% through a reduction in force.acorda therapeutics - expects to realize estimated annualized cost savings related to headcount reduction of approximately $21 million beginning in 2020.acorda therapeutics inc - research and development expenses for full year 2020 are expected to be $20 - $25 million.acorda therapeutics inc - research and development expenses for full year 2019 are expected to be $55 - $60 million, reduced from $70 - $80 million.
ACOR Ratings Summary
ACOR Quant Ranking